Impact of FMT on the Phenome in Patients With NAFLD and Fibrosis

Exclusion Criteria

• •1. Severe or life-threatening food allergy.
• •2. Pregnant or lactating women; or women trying to conceive.
• •3. Patients with suspected or confirmed cirrhosis (as assessed by clinical, radiological or histological criteria).
• •4. Use of particular medications, including:
• •1. Systemic antibiotics within the six weeks prior to study enrolment.
• •2. Immunosuppression that may influence risks related to FMT (including - but not limited to: use of corticosteroids within eight weeks of intervention; use of cytotoxic chemotherapy; use of azathioprine, tacrolimus, mycophenolate mofetil and/or immunosuppressive biologic therapy, e.g. infliximab).
• •3. Use of GLP-1 agonists.
• •5. Patients not expected to survive the duration of the study's follow-up (six months).
• •6. Swallowing difficulties that may preclude safe use of FMT capsules, including oral-motor dyscoordination.
• •7. Alcohol consumption \> 20g/ day.
• •8. Any active cancer (including treatment within the past six months).
• •9. Active infection at the point of recruitment, including COVID-19 infection.
• •10. Prior receipt of a liver transplant.
• •11. BMI \< 23 in Asian potential participants and BMI \< 25 in Caucasians.
• •12. Advanced chronic kidney disease (eGFR \< 30 ml/min).
• •13. Chronic intestinal disease, including coeliac disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, and chronic diarrhoea.
• •14. Prior bariatric surgery.
• •15. Patients unable to undergo MRI scans (e.g. due to the individual having metallic implants).